RT Journal Article
SR Electronic
T1 Screening for Right Ventricular Dysfunction in the Emergency Department Using a Smartphone ECG Analysis Application: An External Validation Study with Acute Pulmonary Embolism Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.08.24307018
DO 10.1101/2024.05.08.24307018
A1 Choi, Yoo Jin
A1 Park, Min Ji
A1 Cho, Youngjin
A1 Kim, Joonghee
A1 Lee, Eunkyoung
A1 Son, Dahyeon
A1 Kim, Seo-Yoon
A1 Soh, Moon Seung
YR 2024
UL http://medrxiv.org/content/early/2024/05/09/2024.05.08.24307018.abstract
AB Background Acute pulmonary embolism (PE) is a critical condition where timely and accurate assessment of right ventricular (RV) dysfunction is important for patient management. Given the limited availability of echocardiography in emergency departments (EDs), an artificial intelligence (AI) application that can identify RV dysfunction from electrocardiograms (ECG) could improve the treatment of acute PE.Methods This retrospective study analyzed adult acute PE patients in an ED from January 2021 to December 2023. We evaluated a smartphone application which analyzes printed ECG to generate digital biomarkers for various conditions including RV dysfunction (QCG-RVDys). The biomarker’s performance was compared with that of cardiologists and emergency physicians.Results Among 116 included patients, 35 (30.2%) were diagnosed with RV dysfunction. The QCG-RVDys score demonstrated significant effectiveness in identifying RV dysfunction, with a receiver operating characteristic - area under the curve(AUC) of 0.895 (95% CI, 0.829-0.960), surpassing traditional biomarkers such as Troponin I (AUC: 0.692, 95% CI: 0.536-0.847) and ProBNP (AUC: 0.655, 95% CI: 0.532-0.778). Binarized based on the Youden Index, QCG-RVDys achieved an AUC of 0.845 (95% CI: 0.778-0.911), with sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 91.2% (95% CI: 82.4-100%), 77.8% (95% CI: 69.1-86.4%), 63.3% (95% CI: 54.4-73.9%), and 95.5% (95% CI: 90.8-100%), respectively, significantly outperforming all the expert clinicians with their AUCs ranging from 0.628 to 0.683.Conclusion The application demonstrates promise in rapidly assessing RV dysfunction in acute PE patients. Its high NPV could streamline patient management, potentially reducing the reliance on echocardiography in emergency settings.Competing Interest StatementJoonghee Kim, MD developed the algorithm and founded a start-up company ARPI Inc. He is the CEO of the company. Youngjin Cho works for the company as a research director. Eunkyoung Lee and Dahyeon Son works for the company as a data scientist. Otherwise, there is no conflict of interest for the other authors.Funding StatementThis research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: RS-2023-00265933)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review board Ajou University Hospital approved the study (IRB No.: AJOUIRB-DB-2024-177), waiving informed consent due to its retrospective design.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors